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The objective of this opinion paper was to identify and describe potential clinical pharmacists’ services
for the prevention and management of patients infected with the hepatitis C virus (HCV). The goals of
this paper are to guide the establishment and development of pharmacy services for patients infected
with HCV and to highlight HCV research and educational opportunities. Recommendations were based
on the following: a review of published data on clinical pharmacist involvement in the treatment and
management of HCV-infected patients; a consensus of clinical pharmacists who provide direct patient
care to HCV-infected patients and practice in different pharmacy models, including community-based
and academic settings; and a review of published guidelines and literature focusing on the treatment
and management of HCV infections. The recommendations provided in this opinion paper define the
areas of clinical pharmacist involvement and clinical pharmacy practice in the treatment and manage-
ment of patients with HCV. Clinical pharmacists can promote preventive measures and education
about reducing HCV transmission, improve medication adherence, assist in monitoring clinical and
adverse effects, recommend treatment strategies to minimize adverse effects and drug interactions, and
facilitate medication acquisition and logistics that positively improve patient outcomes and reduce the
health care system costs.
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Background
Approximately 170 million persons worldwide
are affected by the hepatitis C virus (HCV), and
3.2 million are chronically infected in the United
States.1 About 75–85% of patients with untreated
acute HCV infection will progress to chronic
infection; of these, 45% will develop cirrhosis by
2030.1, 2 In addition, 1–5% of deaths occur from
HCV-related complications of cirrhosis or hepa-
tocellular carcinoma (HCC).1 HCV-related mor-
bidity and mortality are expected to increase
between 2030 and 2035, with 38,000 cases of
end-stage liver disease (ESLD), 3,200 cases
requiring referral for liver transplantation, and
36,100 deaths.3 These statistics are not expected
to improve if current screening rates, public
awareness, and interventions to treat and man-
age HCV infection remain low.3 Recent data
from the 1999–2008 National Health and Nutri-
tion Examination Survey (NHANES) found that
“baby boomers” (persons born between 1945
and 1965) make up 76.5% of all HCV-infected
adults in the United States.4 Therefore, the Cen-
ters for Disease Control and Prevention (CDC),
the U.S. Preventive Services Task Force, the
American Association for the Study of Liver Dis-
ease (AASLD), and the Infectious Diseases Soci-
ety of America (IDSA) recommend a one-time
screening for HCV infection in all baby boomers
who do not have any known risk factors for
acquiring HCV infection.1, 5 The Institute of
Medicine (IOM) reports that in the next
10 years, about 2.7–3.9 million persons will be
chronically infected, and of these, 75% are una-
ware of their infection.6 The IOM report identi-
fied several key issues affecting existing efforts
against viral hepatitis, including a lack of knowl-
edge about HCV infection among the general
public and health care providers.6 Their findings
emphasize the need for increased HCV screening
and the capability to treat HCV-infected persons.
Expansion of HCV testing sites, including com-
munity pharmacies, would allow earlier
detection of infected individuals and more
timely management before complications of liver
disease ensue. The anticipated development and
approval of more effective and tolerable HCV
agents may significantly increase the number of
individuals seeking HCV treatment.
The AASLD recommends initiating antiviral
treatment in HCV-infected persons with bridging
or septal fibrosis or with compensated liver cir-
rhosis observed on liver histology.7 The goals of
HCV therapy are to prevent liver disease pro-
gression to cirrhosis and development of compli-
cations (e.g., portal hypertension, HCC) and
mortality. Identification of HCV genotype (1–7),
including subtype (e.g., 1a, 1b), is essential to
determine the appropriate therapy and length of
treatment. In the United States, 75% of patients
are infected with HCV genotype 1, followed by
genotypes 2 and 3.7, 8 The end point of HCV
treatment is determined by surrogate virologic
parameters rather than by clinical end points.
The primary goal of treatment is to achieve a
virologic cure or a sustained virologic response
(SVR), currently defined as having an undetect-
able HCV RNA level 24 weeks after completion
of therapy, although there is support for the
identification of SVR as early as 12 weeks after
treatment.7, 9
The AASLD practice guidelines for the man-
agement of chronic HCV have undergone signifi-
cant revisions in the past few years based on
emerging data from clinical trials of new HCV
agents. The 2009 AASLD practice guidelines rec-
ommended the combination of ribavirin and pe-
ginterferon alfa-2a or -2b as standard therapy.7
In clinical trials, standard therapy was associated
with SVR rates of approximately 42–52% in
patients with HCV genotype 1 and ~80% for
genotypes 2 and 3.10 In 2011, the first-genera-
tion direct-acting antivirals (DAAs), telaprevir
and boceprevir, were U.S. Food and Drug
Administration (FDA) approved only for geno-
type 1 infection. The addition of the first-genera-
tion DAAs to standard therapy increased SVR
rates by 31% to 47% with telaprevir and by 25%
to 38% with boceprevir (response-guided
therapy).10 Treatment using first-generation
DAAs is not FDA approved for special popula-
tions, including human immunodeficiency virus
(HIV)-HCV–coinfected patients and liver trans-
plant recipients. However, SVR rates in HIV-
HCV–coinfected patients are similar to those
reported in HCV monoinfected patients. Poten-
tial benefits have also been observed in studies
in liver transplant recipients; unfortunately,
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these studies were small, single-center studies,
and only early virologic response (EVR) data
were available.11 Additionally, telaprevir and
boceprevir have significant drug interactions
with calcineurin inhibitors, which limits use of
these agents in transplant patients.11 The AASLD
2011 guidelines recommended starting first-gen-
eration DAAs, in combination with peginterferon
alfa and ribavirin, in patients with genotype 1
infection.12
In January 2014, joint AASLD and IDSA
updated Web-based guideline recommendations
were issued based on encouraging study results
and preliminary data from ongoing trials with
second-generation DAAs and newer agents.5
First-generation DAAs are no longer recom-
mended. The AASLD and IDSA joint guidelines
recommend sofosbuvir- and simeprevir-based
regimens, depending on HCV genotype and eli-
gibility of peginterferon alfa therapy, over first-
generation DAA regimens and peginterferon alfa
and ribavirin combination therapy.5 The second-
generation DAAs, simeprevir (NS3/4A protease
inhibitor) and sofosbuvir (nucleotide analog
NS5B polymerase inhibitor), were both approved
by the FDA for the treatment of HCV genotype
1 infection (including cirrhosis) at the end of
2013.13, 14 Sofosbuvir was also FDA approved in
patients with HCV genotype 2, 3, or 4 infection;
patients with HCC; patients with HCV–HIV-1
coinfection; and those awaiting liver transplanta-
tion.13 Sofosbuvir should be combined with riba-
virin for HCV genotype 2 or 3 and with
peginterferon alfa and ribavirin for HCV geno-
type 1 or 4 infection. Sofosbuvir could also be
combined with simeprevir with or without riba-
virin (off-label use) in patients with genotype 1
infection who are ineligible to receive peginter-
feron alfa therapy. A major advantage of sof-
osbuvir-based therapy is its shorter total
treatment duration of 12–24 weeks, compared
with first-generation DAA therapy (24–
44 weeks). However, patients with genotype 3
infection who received 12 weeks of sofosbuvir
and ribavirin had worse SVR rates (30%) than
those observed with peginterferon alfa and riba-
virin therapy (~60%).15 In the VALENCE study
of 250 patients with genotype 3 infection, SVRs
of 91% and 68% were achieved among those
without and those with cirrhosis, respectively.16
Therefore, genotype 3 patients should receive
24 weeks of sofosbuvir and ribavirin to improve
SVR rates.13, 15, 16 Similar to telaprevir and
boceprevir, 12 weeks of simeprevir should be
used in combination with peginterferon alfa and
ribavirin for a total treatment duration of
24–44 weeks. Unfortunately, some of these
newer regimens still include ribavirin and pegin-
terferon alfa, which are associated with signifi-
cant adverse effects; however, studies showed
that newer regimens are associated with SVR
rates greater than 90% (~60% with genotype 3
infection) and fewer adverse effects compared
with first-generation DAAs and combination pe-
ginterferon alfa and ribavirin therapy.17
Multiple investigational agents are being stud-
ied in interferon-free regimens with or without
ribavirin (e.g., paritaprevir/ritonavir, dasabuvir,
ombitasvir, fixed-dose combination of sofosbuvir
and ledipasvir) and all-oral, interferon-free, and
ribavirin-free regimens (e.g., daclatasvir, asuna-
previr, and BMS-791325 therapy) with promis-
ing results (SVR rates > 90%).17–20 Emerging
agents with activity against genotype 1 infection
include the following: (i) ledipasvir, an HCV
NS5A inhibitor with activity also against geno-
type 4 infection; fixed-dose, coformulated
ledispasvir and sofosbuvir for genotype 1 infec-
tion21–23; (ii) paritaprevir/r, an NS3/4A protease
inhibitor that is combined with ritonavir to
increase its half-life, allowing once-daily dosing;
(iii) ombitasvir, an NS5A replication complex
inhibitor; (iv) dasabuvir, a nonnucleoside NS5B
polymerase inhibitor; (v) daclatasvir, an HCV
NS5A replication complex inhibitor with pan-
genotypic activity against genotypes 2–624; and
(vi) asunaprevir, an NS3 protease inhibitor with
antiviral activity against genotypes 2–6.25, 26
With expanded HCV testing and approval of
new HCV agents and treatment regimens associ-
ated with impressive SVR rates and better tolera-
bility, the demand for HCV treatment is likely to
increase.
Although the current medications used to
treat HCV are effective in achieving SVR, several
limitations are associated with their use. Signifi-
cant adverse effects associated with the adminis-
tration of peginterferon alfa (e.g., depression,
flu-like symptoms, neutropenia, and thrombocy-
topenia) and ribavirin (e.g., hemolytic anemia,
rash, and teratogenicity) have resulted in treat-
ment discontinuation rates of 10–14% and poor
SVR rates.10, 12 The addition of first-generation
DAAs produced new toxicities (e.g., telaprevir-
induced rash; boceprevir-induced anemia and
dysguesia), worsened standard therapy toxicities,
and had complicated drug interactions (sub-
strates and inhibitors of cytochrome P450 [CYP]
3A, P-glycoprotein [P-gp], and organic anion-
transporting polypeptide [OATP] 1B1 and
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OATP2B1 [only with telaprevir]).27 Newer FDA-
approved DAAs have been associated with fewer
toxicities compared with first-generation DAAs.
The most common reported adverse effects with
simeprevir are rash, photosensitivity reactions,
pruritus, and nausea. Fatigue and headache have
been reported with sofosbuvir coadministered
with ribavirin, and fatigue, headache, nausea,
insomnia, and anemia have been reported with
sofosbuvir, peginterferon alfa, and ribavirin.13, 14
Unfortunately, sofosbuvir and simeprevir are
associated with significant drug interactions,
although to a lesser extent compared with those
associated with first-generation DAAs. Sofosbuvir
is a P-gp substrate associated with significant
but fewer drug interactions, primarily with
potent P-gp inducers (e.g., rifampin, carbamaze-
pine, St. John’s wort).13 Simeprevir has the
potential for significantly more drug inter-
actions than sofosbuvir since it is a substrate
and inhibitor of intestinal CYP3A, P-gp, and
OATP 1B1/3.14 Currently, several interferon-free
and ribavirin-free regimens have been studied
and were associated with fewer adverse effects
and drug interactions compared with current
therapy.17–20 Previously, limited data were avail-
able about retreatment with DAAs in patients
who were failing or intolerant to initial DAA-
based regimens; however, the combination of da-
clatasvir and sofosbuvir in patients with HCV
genotype 1 was associated with SVR rates of
98% in patients who did not achieve an SVR
with telaprevir or boceprevir.24
Purpose
The purpose of this opinion paper is to
describe the practice and scope of professional
services of clinical pharmacists in the prevention
and management of HCV infection. This paper
was written as a guide to developing and main-
taining clinical pharmacy services for persons
with HCV infection. It should not necessarily be
expected to serve as a standard of care, nor is it
designed to limit the scope of clinical pharmacy
practice in this setting.
A clinical pharmacist should be a prominent
member of the interdisciplinary team providing
pharmaceutical care for patients with chronic
HCV infection. The roles and responsibilities of
the clinical pharmacist may vary, depending on
the health care setting; federal, state, and local
laws; and institution policies and procedures.
However, we believe that the involvement of a
clinical pharmacist can promote preventive
measures and education on reducing HCV trans-
mission, improve medication adherence, assist in
initiating HCV treatment, assist in monitoring
clinical and adverse effects, recommend treat-
ment strategies for minimizing adverse effects,
and facilitate medication acquisition and logis-
tics that positively improve patient outcomes
and reduce health care system costs.
Establishing Pharmacy Involvement in the Area
of HCV
Identifying Roles and Activities
Several factors should be considered before
initiating HCV treatment, including overall drug
cost, contraindications, treatment benefits, effi-
cacy and duration, drug interactions, pharmac-
ogenomics, and adverse effects. A clinical
pharmacist can prevent and minimize costs
related to adverse effects and drug interactions.
HCV is the most common chronic blood-borne
infection in the United States, and it is associ-
ated with a significant financial burden to the
health care system.28 It is expected that direct
costs alone will exceed $10.7 billion by
2019.28, 29 The majority of the economic
resources directed toward HCV are associated
with medications, laboratory monitoring, and
management of adverse effects. However, the
cost of caring for HCV-infected patients
increases ~18% with disease progression (e.g.,
advanced liver disease) and may exceed
$100,000 annually in patients requiring liver
transplantation.30
Medication costs, especially with DAAs, are
important to consider before starting HCV ther-
apy. Currently, the cost of DAAs can range
from $26,400 to $80,000, depending on the
DAA prescribed and the duration of therapy.
Pharmacogenomics may also influence therapy
costs and assist patients and clinicians in mak-
ing the decision to pursue therapy. Patients
with interleukin (IL)-28B genotype cytosine-
cytosine (CC) were more likely to achieve an
undetectable HCV RNA level after 4 weeks
(rapid virologic response [RVR]) of peginterfer-
on alfa and ribavirin compared with individuals
carrying one or two copies of the thymine (T)
allele (e.g., TT or CT).31 In addition, patients
with the Q80K polymorphism are less likely to
respond to simeprevir therapy, and screening
for this polymorphism is strongly recommended
before initiation of simeprevir for HCV geno-
type 1a infections.14
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The cost of adverse effects can significantly
impact the overall economic analysis associated
with HCV treatment. Peginterferon alfa and riba-
virin are associated with numerous adverse
effects (as described earlier), and the addition of
DAAs can potentiate these toxicities as well as
incur new toxicities.10, 12 Although ribavirin
dose reduction is the preferred initial manage-
ment strategy, severe anemia could necessitate
the use of erythropoietin-stimulating agents
(ESAs) and transfusions and/or result in hospi-
talization.10, 12 For patients receiving ribavirin-
based therapy, ribavirin dose reduction to
600 mg/day can effectively manage anemia with-
out compromising SVR rates and without the
added expense of ESAs.5, 10, 12
Although costs associated with drug acquisi-
tion and management of HCV-related adverse
effects are high, especially with the addition of
DAAs, these costs are offset by preventing
advancing liver disease in patients who success-
fully complete treatment.3 In one study, com-
pared with standard therapy, triple therapy with
boceprevir or telaprevir, peginterferon alfa, and
ribavirin reduced lifetime risk for histological
changes by 38% and 28% and increased quality-
adjusted life expectancy by 3% and 8%,
respectively, in patients with HCV who had mild
and advanced fibrosis.32 Overall, clinical
pharmacists can play a crucial role within the
interprofessional team to facilitate successful
completion of HCV drug treatment by
implementing cost-effective therapies (e.g.,
optimizing treatment response) and effectively
managing adverse effects to prevent worsening
of these events and potential hospitalization. All
of these activities are essential in containing
health care costs.
Managing drug toxicity aggressively and
appropriately is critical to ensure successful
completion of HCV therapy. Treatment discon-
tinuation rates have been reported to be as high
as 14%, especially with peginterferon alfa and
ribavirin therapy.10, 12 Adherence, especially
with the addition of the first-generation DAAs, is
reduced due to the pill burden and complexity
of drug dosing, duration of treatment, and mul-
titude of adverse effects.33 DAA therapy, espe-
cially with first-generation DAAs, is further
complicated by many drug interactions.27 As
drug experts, clinical pharmacists should be an
integral part of the interprofessional team to
facilitate successful HCV therapy by monitoring
for and addressing drug toxicities, improving
adherence, and identifying and addressing drug
interactions before, during, and after HCV
therapy. Clinical pharmacists can also perform
HCV pretherapy screening and education to pre-
pare patients for treatment, which might mini-
mize nonadherence.
Roles of the Clinical Pharmacist and Description
of Activities
The management of HCV infections is cen-
tered on pharmacotherapy, making the clinical
pharmacist appropriately suited as part of the
patient’s care team. Current HCV guidelines
provide recommendations on its diagnosis,
treatment, and management; however, specific
recommendations involving clinical pharmacists
in HCV care do not exist.5 Literature docu-
menting the clinical pharmacist’s role in the
management of HCV describes activities devel-
oped within the ambulatory setting, but most
can be easily extrapolated to the inpatient envi-
ronment. In both the outpatient and inpatient
setting, the clinical pharmacist’s roles and
activities include the following: (i) preventive
care, (ii) comprehensive medication and disease
evaluation, (iii) patient education, counseling,
and adherence evaluation, (iv) cost evaluation
and distribution of medication, (v) pretreat-
ment laboratory assessment and adverse toxic-
ity management, (vi) HCV dosing and
treatment recommendations and assessment of
treatment efficacy, and (vii) transitions of care
activities.
Preventive Care
The clinical pharmacist has an opportunity to
play a key role in the prevention of HCV by
increasing public and individual awareness.6
Additionally, the clinical pharmacist may be
involved in the provision of hepatitis A and B
virus immunizations for those infected with
chronic HCV.5, 10 Patients with known liver dis-
ease are at increased risk of morbidity and mor-
tality should they be infected with other
hepatotrophic viruses (e.g., hepatitis A and B
viruses).5, 10, 12 Additionally, patients with
chronic liver disease should receive an annual
influenza vaccine and pneumococcal polysaccha-
ride vaccine. Other vaccines that can be consid-
ered on an individual basis include tetanus/
diphtheria/pertussis (whooping cough), varicella
zoster, and measles/mumps/rubella. At a mini-
mum, clinical pharmacists should review the
patients’ immunization history and assess the
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need for hepatitis A virus, hepatitis B virus,
influenza, and pneumococcal vaccinations.
Comprehensive Medication and Disease Evaluation
Clinical pharmacists should prospectively
evaluate all drug therapy for appropriate indica-
tions, dosages, and drug interactions and inter-
vene as needed. An assessment of the patient’s
current medications affords the opportunity to
address four major medication-related issues: (a)
identifying medications known or likely to cause
drug interactions with HCV treatment
medications, (b) identifying and assessing the
use of complementary and alternative medicine
(CAM) therapies, (c) identifying and assessing
drug–disease interactions, and (d) optimizing
management of underlying disease states.
(a) Numerous commonly used medications
interact with DAAs (e.g., simeprevir- and ri-
tonavir-containing antivirals) with varying
clinical relevance. Documented and potential
drug interactions should be identified, and
recommendations for monitoring, dosage
adjustments, or changes in therapy should be
anticipated.27 Additionally, the number and
clinical implications of the interactions need
to be evaluated when considering which DAA
is selected. Additional dosage adjustments
and monitoring recommendations should be
reviewed in the prescribing information for
DAAs; however, not all potential drug inter-
actions have been evaluated and/or listed in
the prescribing information. To supplement
this information, pharmacokinetic properties
of medications may be analyzed for the extent
and pathway of metabolism. The clinical sig-
nificance of drug interactions is not always
evident, and clinical pharmacists can aid in
interpreting and guiding therapy. In the
instances where there are no viable therapeu-
tic alternatives, close and frequent monitoring
of the interacting medication and dose titra-
tion should be considered.
(b) In addition to reviewing prescription and
nonprescription medications, it is important
for clinical pharmacists to evaluate the use of
CAM, which is common among patients with
chronic liver disease.34 One study showed
that silymarin (milk thistle) was commonly
used in patients with chronic HCV (16% had
used previously and 17% used regularly) to
modestly improve HCV treatment response
and decrease adverse effects.35 Concomitant
use of silymarin with simeprevir has been
shown to increase levels of simeprevir; there-
fore, clinical pharmacists should recommend
against combining these agents.14 Another
CAM to consider is St. John’s wort, as it has
been shown to decrease serum concentrations
of DAAs.13, 14, 27 Currently, there are no data
regarding drug interactions with other CAM
therapies in patients receiving DAA therapy.
In addition to CAM therapies, clinical phar-
macists should consider drug–food interac-
tions with DAA therapy (e.g., grapefruit juice
with simeprevir); however, this information
is limited.
(c) Drug–disease interactions should also be
evaluated by clinical pharmacists in patients
infected with HCV, especially in assessing
appropriate drug use and dosing in patients
with existing hepatic dysfunction.36, 37 For
example, patients with cirrhosis often use non-
steroidal antiinflammatory drugs (NSAIDs) as
a replacement for acetaminophen for pain
management. However, NSAIDs can cause
kidney dysfunction, reduce the efficacy of
diuretics, and increase the risk of upper gas-
trointestinal hemorrhage, which are all signif-
icant concerns in these patients. If
acetaminophen must be used, clinical phar-
macists should review specific recommenda-
tions regarding acetaminophen dosing in
patients with liver disease (especially used
concurrently with alcohol) and limit the daily
dosage to no more than 2 g. In addition to
assessing home medications used in patients
with cirrhosis, it is important to assess the
use of HCV agents in patients with cirrhosis
(e.g., indication of certain agents in patients
with cirrhosis, such as with simeprevir) and
consider the challenges when managing these
agents in these patients (e.g., worsening
underlying thrombocytopenia with peginter-
feron alfa). Also, the extent of existing hepa-
tic dysfunction in patients with cirrhosis
should be evaluated and used to guide appro-
priate drug use and dosing. In addition to
assessing the use of HCV agents in patients
with cirrhosis, clinical pharmacists should
also be involved in determining the patient’s
eligibility for peginterferon alfa therapy based
on the patient’s psychiatric history, risk of
psychiatric complications, and risks of pegin-
terferon alfa toxicities. Patients should be
evaluated for depression before starting treat-
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ment and regularly during therapy for exacer-
bation of depression, anxiety, or other psychi-
atric illness, especially if receiving
peginterferon alfa therapy.36, 37 Even in
patients not receiving interferon, underlying
depression can affect adherence to therapy.38
Clinical pharmacists can also assist in evaluat-
ing both men and women for appropriate
contraception before initiating HCV treatment
regimens that include ribavirin, a known
teratogen with a long half-life. With the
wealth of drug knowledge that clinical
pharmacists possess, these clinicians are well
positioned to make these recommendations.
(d) A thorough medication evaluation offers an
opportunity to recommend alternative treat-
ments to optimize comorbidities, especially if
patients are working toward candidacy for
HCV treatment but have poorly controlled
underlying disease states. Additional respon-
sibilities of clinical pharmacists include iden-
tifying strategies to reduce pill burden,
recognizing compliance and adherence issues,
and motivating patients to become active par-
ticipants in their treatment. Optimizing ther-
apy for underlying disease states (e.g.,
diabetes mellitus) and general lifestyle inter-
ventions including weight loss and cessation
or reduction of alcohol, marijuana, and
tobacco, which have been associated with
worsening liver damage, should also be
implemented.39 For example, a clinical phar-
macist can evaluate underlying disease states
at each appointment and reach out to the
patient’s health care providers (e.g., primary
care physician) to make recommendations to
optimize treatment for these disease states as
needed.
Patient Education, Counseling, and Adherence
Evaluation
The shortage of primary care providers and
the sparse availability of specialized clinics
designed specifically for HCV management may
limit a prescriber’s ability to dedicate sufficient
time to provide extensive disease state and medi-
cation counseling. Many health care providers
may avoid treating patients with HCV because of
the complexity and unfamiliarity of the
treatment regimen. Significantly improved
clinical outcomes, patient satisfaction, and
pharmacoeconomics have been reported when
clinical pharmacists provide disease state
counseling and medication education for multi-
ple chronic diseases.40 An interprofessional
approach involving clinical pharmacists in HCV
management demonstrated community-based
SVR rates comparable to those achieved in clini-
cal trials.41 As an integral clinician on the inter-
professional team, clinical pharmacists could
provide patient-specific drug and disease state
education during initial and follow-up visits for
HCV treatment. Effective counseling has been
shown to positively impact patient adherence to
HCV therapy, increasing SVR rates to 60% in
patients who received combination therapy with
peginterferon alfa and ribavirin.36 Additionally,
patients infected with chronic HCV genotype 1
who were adherent to more than 80% of their
treatment doses of peginterferon alfa and ribavi-
rin achieved higher SVR rates.33 Overall,
improvement in adherence could impact viral
resistance and efficacy of future treatment
options.
Adherence has been a common concern with
HCV therapy, historically due to significant pill
burden and complex dosing regimens.
Although current treatments are substantially
easier and new therapies are expected to be
even more so, new concerns for adherence
have arisen, especially in the context of medi-
cation costs and patients taking medications
for multiple comorbidities. Clinical pharmacists
are well suited to help patients incorporate
HCV therapy into their daily activities and to
make treatment recommendations based on
their assessment of the patient’s risk of nonad-
herence. Clinical pharmacists should use any
tools available to assist patients in achieving
compliance, including the use of pill boxes
and reminder alarms and engaging supportive
family members. Clinical pharmacists should
also assess whether patients have adequate
medication storage areas (e.g., a functional
refrigerator) and stress the important of appro-
priate storage of HCV medications.
Another component of patient education is
instructing patients on how to safely and effec-
tively administer injections, such as peginterfer-
on alfa and growth factors (e.g., ESAs and
granulocyte colony-stimulating factor [G-CSF]).
A review of proper injection techniques can be
provided by the clinical pharmacist at therapy
initiation and reiterated at follow-up visits. Addi-
tionally, the clinical pharmacist may educate
patients on potential adverse effects that may
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develop during the course of HCV therapy,
encourage patients to actively participate in their
medical care, and discourage self-discontinua-
tion of these essential medications. Chronic dis-
ease support groups and educational classes
focusing on HCV infection are also effective set-
tings for the clinical pharmacist to provide
expert knowledge on managing HCV while pro-
viding the patient and family members a com-
fortable environment to ask questions and
address any treatment concerns.42
Cost Evaluation and Distribution of Medication
Involvement in procurement and distribution
of medication offers another opportunity for
clinical pharmacists to optimize therapy in
patients with HCV and to ensure treatment
adherence.37 Clinical pharmacists can identify
patients at risk for nonadherence based on refill
histories of other medications. A clinical phar-
macist involved in the distribution and dispens-
ing of medication can ensure that the patient
receives medications on time, streamline the
prior authorization process, and ensure that all
medications are updated in the pharmacy system
to review for potential drug interactions. In
addition to assisting with medication distribu-
tion, clinical pharmacists should identify and
address cost-related issues before the patient
starts HCV treatment. Health care providers
might overlook the patient’s inability to afford
HCV medications due to lack of insurance, high
deductibles, or high copayments. As mentioned
previously, medications used to treat HCV are
extremely expensive, and when cost-related
issues arise, clinical pharmacists can identify
potential cost-saving sources (e.g., medication
assistance programs or copay card programs).
Pretreatment Laboratory Assessment and Adverse
Toxicity Management
Review of baseline laboratory results (e.g.,
HCV viral load, pharmacogenomics testing,
hemoglobin, and hematocrit) allows a clinical
pharmacist to gauge treatment response and to
predict potential adverse effects that may occur
with HCV therapy. For example, anemia is an
expected adverse event that can occur with HCV
therapy, especially when ribavirin is used. In an
anemic patient, investigation and management of
the anemia should be performed before the
initiation of HCV treatment to prevent further
decline.
Adverse effects have been reported, in vary-
ing severity, in up to 94% of patients receiving
peginterferon alfa and ribavirin therapy, limit-
ing completion of the HCV treatment
course.36, 37 However, one study involving clin-
ical pharmacists in the treatment of patients
infected with the HCV genotype 1 showed that
only 12% of patients required medical treat-
ment of their adverse effects, and early discon-
tinuation of HCV therapy occurred in 6% of
patients.37 Clinical pharmacists at the point-of-
care and point-of-dispensing can identify these
adverse effects early and initiate appropriate
strategies to minimize complications and treat-
ment discontinuation. For example, clinical
pharmacists can assist health care providers in
monitoring laboratory test results, specifically
for anemia, neutropenia, and thrombocytopenia.
If adjunctive therapies are required, such as
ESAs or G-CSF, the clinical pharmacist can
identify and resolve cost issues of these expen-
sive drugs (e.g., insurance coverage or cost to
the patient) and recommend an appropriate
drug regimen. Clinical pharmacists can also
assist other health care providers in managing
the development or exacerbation of emotional
or cognitive impairment, such as depression or
irritability, as patients with chronic HCV have
higher rates of these conditions.43 Psychiatric
adverse effects have been reported frequently
with peginterferon alfa, including worsening of
underlying psychiatric illnesses.38 Depression
from peginterferon alfa has been reported to be
a risk factor for treatment failure and to nega-
tively impact treatment adherence and quality
of life.38 Therefore, patients should be evalu-
ated for depression before starting treatment
and regularly during therapy for exacerbation
of depression or psychiatric illness.10 Antide-
pressants are often prescribed to prevent and
ameliorate interferon-induced depressive symp-
toms and allow successful completion of HCV
therapy; however, some of these medications
interact with DAA therapy.27, 36, 44 Clinical
pharmacists can assist other health care provid-
ers in implementing and managing an effective
antidepressant regimen to minimize any poten-
tial adverse effects and/or drug interactions,
thereby affording patients the best chance of
achieving treatment success.36, 44 Interferon-free
and interferon and ribavirin–free regimens will
likely minimize the concerns for psychiatric
adverse effects. Clinical pharmacists can assist
in making recommendations on an appropriate
treatment regimen for these patients.
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HCV Dosing and Treatment Recommendations and
Assessment of Treatment Efficacy
Clinical pharmacists, in collaboration with
the primary health care provider, should rec-
ommend therapy and initial dosing of medica-
tions. For example, in patients with prior rash
history, simeprevir might be avoided when a
recurrence of rash would be especially challeng-
ing. Patients with multiple comorbidities and
concomitant medications may be better suited
to start sofosbuvir because of its shorter treat-
ment duration and fewer drug interactions,
thereby limiting the number of potential drug
interactions and time frame of intolerance.
Clinical pharmacists should also determine
appropriate concomitant HCV medications to
use with DAA therapy. Appropriate duration of
HCV therapy and use of HCV therapy in spe-
cial patient populations (e.g., patients with
HIV-HCV coinfection, HCC, or cirrhosis, or
liver transplant recipients) should also be eval-
uated by clinical pharmacists before initiation
of therapy. Insurance companies cover certain
HCV medications based on specific indications
and costs. For example, an insurance company
could approve sofosbuvir in patients infected
with HCV genotype 1, 2, or 4, while limiting
HCV therapy to combination peginterferon alfa
and ribavirin in patients infected with HCV
genotype 3. Clinical pharmacists must consider
insurance and institutional formularies when
selecting specific HCV agents.
Additionally, before the initiation of HCV
therapy, clinical pharmacists should evaluate
pharmacogenomics that may influence treatment
efficacy and costs. Testing for the IL-28B
genotype may be considered for peginterferon-
alfa–eligible patients, whereas the Q80K
polymorphism should be screened for in geno-
type 1a–infected patients receiving simeprevir,
especially those failing first-generation DAAs
who may harbor mutations. In addition to
pharmacogenomics, clinical pharmacists may
consider evaluating the patient for resistance
mutations, especially since these mutations show
cross-resistance to many HCV drugs.31
During and after HCV treatment, clinical
pharmacists should assess treatment efficacy. In
patients with HCV genotype 1, serum HCV RNA
levels are measured during treatment depending
on the HCV regimen to assess patient response.
This test should be repeated at the end of
treatment to document the end-of-treatment
response (ETR). Final testing should be done
after treatment to determine whether an SVR has
been achieved.10, 12 For genotypes 2–6, HCV
RNA testing may be performed for RVR and
EVR, but it should be performed in all patients
for ETR and SVR.7, 10, 12 Clinical pharmacists
can ensure that patients who do meet the futility
rules (i.e., rules developed during clinical trials
that specify the HCV RNA threshold [e.g.,
> 1000 IU/ml] at the specific week of therapy
for when to discontinue a given treatment to
prevent needless drug exposure and minimize
development of resistance) should discontinue
HCV therapy.
Transitions of Care Activities
The clinical pharmacist can play a vital role
in the management of HCV in patients trans-
ferring from one health care setting to another
(e.g., from home to hospital). Patients receiving
HCV care may be managed by HCV specialists,
and if admitted to the hospital, these patients
are cared for by general medicine practitioners
or hospitalists. Clinical pharmacists have the
opportunity to educate health care providers
about the importance of HCV treatment contin-
uation, adverse events, and drug interactions.
HCV medications might be discontinued during
a hospital admission; however, clinical pharma-
cists are well positioned to ensure therapy con-
tinuation by identifying these medications
through medication reconciliation and by facili-
tating medication acquisition. Studies have
shown that more accurate and comprehensive
medication histories are obtained by pharmacy
personnel compared with other health care
professionals.45, 46 Facilitating medication
acquisition is important, especially if hospital-
ized patients forget to bring in their HCV med-
ications from home. This is crucial, since
missed doses of HCV medications, especially
first-generation DAAs, may result in HCV resis-
tance and treatment failure. HCV medications
are costly; therefore, many hospitals do not
have these drugs readily available on their for-
mulary, forcing treatment interruptions. Clini-
cal pharmacists can assist these practitioners or
hospitalists by identifying and managing issues
associated with HCV medications to ensure
successful and safe continuation of HCV treat-
ment. Clinical pharmacists can also assist in
evaluating HCV therapies to include in-hospital
and health system formularies to ensure appro-
priate use of these medications and drug avail-
ability.
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Planning and Implementation
Clinical pharmacist involvement in the care of
patients infected with HCV is specific to a prac-
tice setting; thus, design and required resources
will depend on patient and provider needs. The
business plan is the first critical step and should
take into account the practice environment and
its needs. It should contain the clinical pharma-
cist’s scope of practice and location of services.
The services should be marketed to the right cli-
ents, and obtaining input from key stakeholders
is paramount in the planning process. Imple-
menting services with physicians or practices
makes fine-tuning the program and measuring
outcomes easier. Demonstrating positive out-
comes will improve extension to more physi-
cians and practices. Potential outcomes may
include improving adherence, patient satisfac-
tion, improved SVR rates, and/or economic ben-
efit by freeing up clinicians to perform other
clinic-related functions. There should be contin-
uous quality improvement to evaluate and
improve the services provided.47
Documentation
Clinical pharmacists involved in the treatment
of HCV should document all interventions and
recommendations including pretreatment visits
and evaluation of a patient’s baseline medications
(e.g., prescription and nonprescription medica-
tions as well as CAM) and assessment of any
existing or potential drug interactions with HCV
therapy. Additionally, clinical pharmacists should
document all activities related to patient counsel-
ing and adherence. During HCV treatment, clini-
cal pharmacists should consult with other health
care providers and provide clear recommenda-
tions for dosage adjustments of HCV therapy and
concurrent medications, and the use of support-
ive medications (e.g., growth factors).
Education of Other Health Care Professionals
In 2010, the IOM released a report on the
state of HCV in the United States identifying
major gaps in knowledge regarding viral hepati-
tis, not only among the general public but also
among health care and social service providers.6
Clinical pharmacists can facilitate the screening
of HCV-positive patients to improve awareness
of HCV, especially with a focus on the CDC’s
current recommendations for the birth-cohort
(baby boomers) HCV screening. Although not
all patients may be candidates for therapy, edu-
cation regarding HCV can help minimize the
risks of transmission. Clinical pharmacists are
well positioned to provide education regarding
HCV treatment and its complications to other
health care professionals. Patients with HCV are
usually cared for by hepatologists, gastroenterol-
ogists, infectious diseases specialists, and other
providers when admitted to the hospital or when
followed in the outpatient setting. More outpa-
tient clinicians (e.g., primary care physicians)
are prescribing and monitoring HCV treatment,
and this trend may continue as peginterferon
alfa and ribavirin use declines with more effec-
tive oral regimens. Knowledgeable clinical phar-
macists are well positioned to provide education
to patients and providers and to help address
the complex issues with HCV therapy.
Research
Treatment of HCV affords various research
opportunities. As therapy evolves, clinical phar-
macists should be involved in clinical trials of
new therapies and contribute to the literature
regarding the use of current therapies in various
patient populations. There are ongoing trials
evaluating the use of DAA therapy in HIV-HCV–
coinfected patients and in liver transplant recipi-
ents. Significant drug interactions limited the
use of DAAs in these patients, especially after
liver transplantation. Although sofosbuvir is
FDA approved in patients with HIV-HCV coin-
fection who are receiving antiretroviral agents,
sofosbuvir should not be coadministered with ri-
tonavir-boosted tipranavir. In addition, concrete
recommendations on dosage adjustments for
concomitant medications during DAA therapy
are unavailable, and general recommendations
exist (i.e., “caution should be used and dose
reduction should be considered”). Also, there
are limited data regarding the outcomes of these
drug interactions in patients with HCV. Under-
standing the drug interaction potential of new
agents is critical for effective and safe manage-
ment of HCV.11 Moreover, new therapies are
anticipated within the next 1–5 years that will
likely pose new challenges and revise the cur-
rent context of therapy. Clinical pharmacists
should initiate and/or actively collaborate with
other health care providers on various types of
research, including efficacy and safety, pharma-
cokinetic, and pharmacoeconomic studies.48
Clinical pharmacists can contribute to HCV
research in several ways that include, but are
1350 PHARMACOTHERAPY Volume 34, Number 12, 2014
not limited to, the following: (i) participate in
research design and data analysis, (ii) secure
funding to conduct research, and (iii) report
results of clinical research and pharmacoeco-
nomic analyses at regional and national meet-
ings, and publish findings in journals
disseminated to clinical pharmacists and other
health care professionals.
Resources
At a minimum, the clinical pharmacist should
have several resources such a computer and tele-
phone and adequate private space for interview-
ing and educating patients. In an ambulatory
clinic, allocating this type of space can be a
challenge. If a local pharmacy dispenses the
medications, patients can be educated at the
pharmacy. The area needs to be private and
large enough to accommodate a patient with or
without family members, or several patients if
group teaching is provided. However, being able
to interview patients and provide patient educa-
tion in the ambulatory setting is ideal and allows
the clinical pharmacist to build rapport with
their health care providers and staff. Procedures
for the office staff to schedule patients and com-
municate patient needs to the clinical pharma-
cist when he or she is off site should be
developed. Teleconferences provided by spe-
cialty pharmacies and ambulatory clinics may be
an option to provide education and a resource
for patients at off hours and/or when the clinical
pharmacist is off site or for patients residing in
rural areas. Education materials tailored to the
site are necessary and can supplement the teach-
ing material provided by pharmaceutical compa-
nies. These materials should include specific
drug-related information but also adverse effect
management. Pocket cards with the medication
dosing schedule or battery-operated timers can
remind patients to take their medication. A
patient’s consent is recommended to document
the patient’s understanding of the need for
adherence, routine laboratory testing, office vis-
its, adverse effects, and two methods of birth
control. Providing a calendar of laboratory dates
and a packet containing the patient’s laboratory
orders for the duration of treatment will likely
increase adherence to monitoring.
Electronic medical records allow the clinical
pharmacist to view patient charts, communicate
with health care providers and staff, and docu-
ment clinical activities from any location. Also, a
robust computer program that tracks the status
of a patient’s prescription is particularly useful
to the ambulatory-based clinical pharmacist. The
process of insurance approval with prior autho-
rization and the frequent need for patient assis-
tance programs can take several weeks. At any
given time, patients will be in different stages of
the procurement process. A real-time system
organizes this process and is appealing to outpa-
tient ambulatory clinics.
Requirements and Development of Clinical
Pharmacists
Clinical pharmacists providing care to patients
infected with HCV should demonstrate compe-
tency in the knowledge and skills to serve this
unique population. Postgraduate training will
provide a foundation for providing clinical ser-
vices to patients in various settings. However,
specific experiences in caring for patients with
HCV may be limited or not available throughout
the postgraduate training. Therefore, programs
and other experiences should be used to ensure
that clinical pharmacists obtain essential infor-
mation before providing proficient pharmaceuti-
cal HCV care to these patients. Important
information to obtain before caring for these
patients includes pathophysiology of the disease,
recognition and management of drug toxicity
and potential drug interactions, injection train-
ing, and effective patient counseling techniques.
Guideline documents and online modules (e.g.,
the American College of Clinical Pharmacy’s
Ambulatory Care Self-Assessment Program chap-
ter on viral hepatitis49) can be used for the
didactic portion of the program, with an assess-
ment activity to document successful comple-
tion. In addition, sufficient opportunity for
experience in the practice environment to
develop competency in the area of HCV is essen-
tial. Training or mentoring by a clinical pharma-
cist with practice-related experience in
hepatology or infectious diseases is ideal. A
future certificate program for treatment of
chronic HCV could prepare a larger number of
clinical pharmacists in a consistent fashion.
Barriers
Although significant opportunities exist for
clinical pharmacists to provide pharmaceutical
care to patients with chronic HCV infection, sev-
eral common barriers exist that must be over-
come to establish a successful pharmacy service.
Time, provider awareness of clinical pharmacists’
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value and expertise, clinical pharmacists’ confi-
dence and skill, medical record documentation,
and the lack of provider billing status can all be
potential barriers that must be planned for and
addressed.
Educating individual patients initiating treat-
ment for chronic HCV is a lengthy process.
Time and financial constraints might necessitate
group training instead of private training. In a
group setting, patients might feel uncomfortable
asking questions and causing personal needs not
to be addressed or met. After treatment begins,
frequent patient contact is necessary to manage
adverse effects and monitor adherence.
Providers might be unaware of the value that
clinical pharmacists can provide to the chroni-
cally infected HCV patient. Although it may not
represent the prevailing opinion of all practicing
providers, several medical organizations have
expressed concern that clinical pharmacists are
encroaching on areas traditionally performed by
other health care providers.50 Clear communica-
tion, scope of practice, and involvement of pro-
viders in the planning process are important to
demonstrate the value of clinical pharmacists in
HCV care and avoid negative interactions.50 A
collaborative, multidisciplinary approach to the
management of common and complex disease
states, such as HCV, is encouraged.
Clinical pharmacists may lack the confidence
and expertise to manage a HCV-infected patient
without appropriate training or mentoring,
which consists of postgraduate training in addi-
tion to clinical experiences in caring for these
patients. The cost and logistics of developing
and delivering a program to clinical pharmacists
with different levels of experience can be sub-
stantial. Conferences and online courses are
available to clinical pharmacists wanting to learn
more about HCV infection; Appendix 1 provides
a listing of available resources. In addition,
health care delivery models such as Project
ECHO can provide HCV expertise and support
in HCV management.
Clear and effective methods of communicating
recommendations, accessible clinic notes, and
provider education are critical to the successful
HCV pharmacy service. In large specialty phar-
macies, telecommunication is common, but
there can be significant communication barriers
with this style (e.g., lack of visual assessment of
patient comprehension). Not all ambulatory care
clinics have electronic health records, making
remote access to the patient chart impossible. A
paper chart must be physically obtained, and
documentation of outcomes is more tedious.
Conclusion
The demand for HCV treatment is predicted to
increase with expanded HCV testing and the
approval of new HCV drugs associated with
impressive SVR rates and better tolerability. Cur-
rent medications used to treat HCV-infected
patients are effective in achieving SVR. Unfortu-
nately, these drugs are associated with significant
adverse effects (e.g., depression, flu-like symp-
toms, anemia, neutropenia, and thrombocytope-
nia), significant drug interactions with DAAs
(especially with simeprevir and regimens that
include ritonavir), high risk of patient nonadher-
ence and treatment discontinuation, and signifi-
cant medication- and therapy-related costs. Due
to these pharmacological challenges with HCV
treatment, clinical pharmacist involvement in the
treatment of HCV is critical. There is a shortage of
clinicians to manage and treat the HCV epidemic,
and this gap in the health care system is an oppor-
tunity for increased involvement by clinical phar-
macists. In addition, the field of HCV therapy is
rapidly evolving and will require an interprofes-
sional approach to judiciously and effectively
guide pharmacological therapy. Clinical pharma-
cists can play a critical role within the multidisci-
plinary team to facilitate successful completion of
HCV therapy by implementing cost-effective
treatment of HCV (e.g., assessing treatment
response), managing adverse effects effectively,
predicting and managing drug interactions, and
averting potential treatment discontinuation and
hospitalizations. The inclusion of a clinical phar-
macist can promote preventive measures on
reducing HCV transmission, improve medication
adherence, monitor clinical and adverse effects,
optimize HCV medication dosing, improve man-
agement of adverse effects, aid in medication
acquisition and logistics, and subsequently posi-
tively affect patient outcomes.
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Appendix 1. Available Resources on Hepatitis
C Viral Infection
Associations:
American Association for the Study of Liver
Diseases (AASLD)
American College of Gastroenterology (ACG)
American Gastroenterological Association
(AGA)
American Liver Foundation
Web sites:
http://www.clinicaloptions.com/Hepatitis.aspx
http://www.hep-druginteractions.org/
http://echo.unm.edu/
http://www.liverfoundation.org/
http://www.hepatitis.va.gov/
http://www.hcvguidelines.org
http://hepatitisc.uw.edu/index.php
http://www.aasld.org/LiverLearning%C2%AE/
Pages/LiverProgramforPrimaryCareProvid-
ers.aspx
Meetings:
Digestive Disease Week (www.ddw.org):
occurs annually, usually in May
The Liver Meeting (www.aasld.org): occurs
annually, usually in November
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